Cited by 559Bone health and osteoporosis researchMenopause: Health Impacts and TreatmentsBone health and treatments

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

Van Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., Cooper, C.·2003·Arthritis & Rheumatism

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To evaluate predictors of vertebral fractures, including a threshold for bone mineral density (BMD), in patients receiving oral glucocorticoids (GCs). METHODS: Data were obtained from 2 randomized clinical trials (prevention and treatment trials of risedronate) using similar methods, but different inclusion criteria were applied with regard to prior exposure to GCs. Predictors of vertebral fracture in the placebo group were identified using Cox regression with forward selection. The BMD threshold analysis involved a comparison of the 1-year fracture risk in postmenopausal women receiving placebo in the GC trials with that in postmenopausal women not taking GCs in 3 other trials. RESULTS: The study population comprised 306 patients with baseline and 1-year followup data on vertebral fractures (111 receiving placebo and 195 receiving risedronate). In the placebo group, the statistically significant predictors of incident fracture were the baseline lumbar spine BMD (for each 1-point decrease in T score, relative risk [RR] 1.85, 95% confidence interval [95% CI] 1.06-3.21) and the daily GC dose (for each 10-mg dose increase, RR 1.62, 95% CI 1.11-2.36). In the BMD threshold analysis, compared with nonusers of GCs, patients receiving GCs were younger, had a higher BMD at baseline, and had fewer prevalent fractures; nevertheless, the risk of fracture was higher in the GC users compared with nonusers (adjusted RR 5.67, 95% CI 2.57-12.54). The increased risk of fracture was observed in GC users regardless of whether osteoporosis was present. CONCLUSION: The daily, but not cumulative, GC dose was found to be a strong predictor of vertebral fracture in patients receiving GCs. At similar levels of BMD, postmenopausal women taking GCs, as compared with nonusers of GCs, had considerably higher risks of fracture.

Integrity signals

Registry

Crossref · 10.1002/art.11283

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Harris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 3×
“Osteocyte apoptosis is prevalent in GC-induced osteoporosis (24), and preliminary results of an animal study demonstrated that osteocyte viability was an important determinant of bone strength independent of BMD (25).”
BackgroundResult
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Use of Inhaled Corticosteroids and Risk of Fractures
van Staa, T. P., Leufkens, H. G. M., & Cooper, C. C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.581 · Cited by 1,297
Self-citation
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Self-citation
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Self-citation
Dose-Response and Trend Analysis in Epidemiology
Greenland, S. (1995) · Epidemiology · doi:10.1097/00001648-199507000-00005 · Cited by 1,086
Recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis
American College of Rheumatology task force on Osteoporosis guidelines (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391104 · Cited by 848

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 3

1996, SAS/GRAPH software: reference version 6
Johnell O, 2002, Oral corticosteroids increase fracture risk independently of BMD, Osteoporos Int, 13, S14
Weinstein RS, 2002, Preservation of osteocyte viability by bisphosphonates contributes to bone strength in glucocorticoid‐treated mice independently of BMD: an unappreciated determinant of bone strength, J Bone Miner Res, 17, S156

Sorted by citations

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
Papaioannou, A., Morin, S. N., Cheung, A. M., Atkinson, S. A., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A. B., Jamal, S. A., Kaiser, S., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,768
Epidemiology, etiology, and diagnosis of osteoporosis
Lane, N. E. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.08.047 · Cited by 1,300
From Estrogen-Centric to Aging and Oxidative Stress: A Revised Perspective of the Pathogenesis of Osteoporosis
Manolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,234
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
CANALIS, E. M., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,131
Glucocorticoids Act Directly on Osteoblasts and Osteocytes to Induce Their Apoptosis and Reduce Bone Formation and Strength
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2003) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Glucocorticoid-Induced Bone Disease
Weinstein, R. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1012926 · Cited by 711
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C.-S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60250-6 · Cited by 527
Self-citation
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial
Saag, K. G., Zanchetta, J. R., Devogelaer, J., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K., & Warner, M. R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24879 · Cited by 493
Glucocorticoid-induced osteoporosis: an update
Compston, J. E. (2018) · Endocrine · doi:10.1007/s12020-018-1588-2 · Cited by 494
ACG clinical guideline: Preventive care in inflammatory bowel disease
Farraye, F. A., Melmed, G. Y., Lichtenstein, G. R., & Kane, S. V. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.537 · Cited by 473
Epidemiology of Vertebral Fractures
Schousboe, J. T. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.08.004 · Cited by 459
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
Hoes, J. N., Jacobs, J. W. G., Boers, M., Boumpas, D., Buttgereit, F., Caeyers, N., Choy, E., Cutolo, M., da Silva, J. A. P., Esselens, G., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.072157 · Cited by 416
The epidemiology of glucocorticoid-associated adverse events
McDonough, A. K., Curtis, J. R., & Saag, K. G. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282f51031 · Cited by 408
Management of osteoporosis in postmenopausal women
(2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181c617e6 · Cited by 390
Glucocorticoid-Induced Osteoporosis and Osteonecrosis
Weinstein, R. S. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.004 · Cited by 372
Glucocorticoid-induced osteoporosis: an update
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362
High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study
Angeli, A., Guglielmi, G., Dovio, A., Capelli, G., de Feo, D., Giannini, S., Giorgino, R., Moro, L., & Giustina, A. (2006) · Bone · doi:10.1016/j.bone.2006.02.005 · Cited by 362
Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice
Lane, N. E., Yao, W., Balooch, M., Nalla, R. K., Balooch, G., Habelitz, S., Kinney, J. H., & Bonewald, L. F. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051103 · Cited by 355
Secondary Osteoporosis
Ebeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 368
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force
Strehl, C., Bijlsma, J. W. J., de Wit, M. P. T., Boers, M., Caeyers, N., Cutolo, M., Dasgupta, B., Dixon, W. G., Geenen, R., Huizinga, T. W. J., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208916 · Cited by 345
MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management
Mirza, F., & CANALIS, E. M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0118 · Cited by 343
Glucocorticoid-induced osteoporosis
Briot, K., & Roux, C. (2015) · RMD Open · doi:10.1136/rmdopen-2014-000014 · Cited by 300
Fracture risk with intermittent high‐dose oral glucocorticoid therapy
de Vries, F., Bracke, M., Leufkens, H. G. M., Lammers, J. J., Cooper, C. C., & van Staa, T. P. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22294 · Cited by 297
Self-citation
Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update
Suzuki, Y., Nawata, H., Soen, S., Fujiwara, S., Nakayama, H., Tanaka, I., Ozono, K., Sagawa, A., Takayanagi, R., Tanaka, H., et al. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0586-6 · Cited by 281
Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice
Weinstein, R. S., Wan, C., Liu, Q., Wang, Y., Almeida, M., O’Brien, C. A., Thostenson, J., Roberson, P. K., Boskey, A. L., Clemens, T. L., et al. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2009.00545.x · Cited by 276
The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use
Manson, S. C., Brown, R. E., Cerulli, A., & Vidaurre, C. F. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.01.003 · Cited by 279
Bone turnover markers: use in osteoporosis
Naylor, K. E., & Eastell, R. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.86 · Cited by 266
Drug-induced Osteoporosis: Mechanisms and Clinical Implications
Mazziotti, G., CANALIS, E. M., & Giustina, A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.02.028 · Cited by 259
The Pathogenesis, Epidemiology and Management of Glucocorticoid-Induced Osteoporosis
van Staa, T. P. (2006) · Calcified Tissue International · doi:10.1007/s00223-006-0019-1 · Cited by 257
Corticosteroid-Induced Adverse Events in Adults
Fardet, L., Kassar, A., Cabané, J., & Flahault, A. (2007) · Drug Safety · doi:10.2165/00002018-200730100-00005 · Cited by 256
Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice
Yao, W., Cheng, Z., Busse, C., Pham, A., Nakamura, M. C., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23454 · Cited by 241
Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives
Seibel, M. J., Cooper, M. S., & Zhou, H. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70045-7 · Cited by 235
Vertebral Fracture Assessment: The 2007 ISCD Official Positions
Schousboe, J. T., Vokes, T., Broy, S. B., Ferrar, L., McKiernan, F., Roux, C., & Binkley, N. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.12.008 · Cited by 214
Medication-induced osteoporosis: screening and treatment strategies
Panday, K., Gona, A., & Humphrey, M. B. (2014) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x14546350 · Cited by 207
Effects of Collagen Crosslinking on Bone Material Properties in Health and Disease
Saito, M., & Marumo, K. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9985-5 · Cited by 200
Influence of drugs on vitamin D and calcium metabolism
Gröber, U., & Kisters, K. (2012) · Dermato-Endocrinology · doi:10.4161/derm.20731 · Cited by 203
Management of glucocorticoid-induced osteoporosis
Compston, J. E. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.259 · Cited by 193
Glucocorticoid-induced osteoporosis: 2019 concise clinical review
Adami, G., & Saag, K. G. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04906-x · Cited by 191
Osteocyte-Intrinsic TGF-β Signaling Regulates Bone Quality through Perilacunar/Canalicular Remodeling
Dole, N. S., Mazur, C. M., Acevedo, C., Lopez, J. P., Monteiro, D. A., Fowler, T. W., Gludovatz, B., Walsh, F., Regan, J. N., Messina, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.115 · Cited by 173
Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments
Lane, N. E. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00498-x · Cited by 175
Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial
Glüer, C.-C., Marin, F., Ringe, J. D., Hawkins, F., Möricke, R., Papaioannu, N., Farahmand, P., Minisola, S., Martínez, G., Nolla, J. M., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1870 · Cited by 171
COPD and osteoporosis: links, risks, and treatment challenges
Inoue, D., Watanabe, R., & Okazaki, R. (2016) · International Journal of COPD · doi:10.2147/copd.s79638 · Cited by 174
Prevalence of Vertebral Fractures in Men with Acromegaly
Mazziotti, G., Bianchi, A., Bonadonna, S., Cimino, V., Patelli, I., Fusco, A., Pontecorvi, A., De Marinis, L., & Giustina, A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0791 · Cited by 169
Glucocorticoids and bone: Local effects and systemic implications
Henneicke, H., Gasparini, S. J., Brennan-Speranza, T. C., Zhou, H., & Seibel, M. J. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.006 · Cited by 168
Glucocorticoid-induced osteoporosis: who to treat with what agent?
Rizzoli, R., & Biver, E. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.188 · Cited by 169
Glucocorticoid-induced osteoporosis: An update on effects and management
Buehring, B., Viswanathan, R. K., Binkley, N., & Busse, W. W. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.08.040 · Cited by 163
Determinants of imminent fracture risk in postmenopausal women with osteoporosis
Barron, R., Oster, G., Grauer, A., Crittenden, D. B., & Weycker, D. A. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05294-3 · Cited by 160
A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids
van Staa, T. P., Geusens, P., Pols, H. A. P., Laet, C. E. D. H. D., Leufkens, H. G. M., & Cooper, C. C. (2005) · QJM · doi:10.1093/qjmed/hci029 · Cited by 160
Self-citation
Secondary Osteoporosis and Metabolic Bone Diseases
Sobh, M., Abdalbary, M., Elnagar, S., Nagy, E., Elshabrawy, N. A., Abdelsalam, M., Asadipooya, K., & El-Husseini, A. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092382 · Cited by 165
Glucocorticoid dose determines osteocyte cell fate
Jia, J., Yao, W., Guan, M., Dai, W., Shahnazari, M., Kar, R., Bonewald, L., Jiang, J. X., & Lane, N. E. (2011) · The FASEB Journal · doi:10.1096/fj.11-182519 · Cited by 157
Advances in Glucocorticoid-Induced Osteoporosis
den Uyl, D., Bultink, I. E. M., & Lems, W. F. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-011-0173-y · Cited by 154
Longitudinal patterns in the prevention of osteoporosis in glucocorticoid‐treated patients
Curtis, J. R., Westfall, A. O., Allison, J. J., Becker, A., Casebeer, L. L., Freeman, A. N., Spettell, C. M., Weissman, N., Wilke, S., & Saag, K. G. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21194 · Cited by 152
Vertebral Fracture Assessment: The 2005 ISCD Official Positions
Vokes, T., Bachman, D. M., Baim, S., Binkley, N., Broy, S. B., Ferrar, L., Lewiecki, E. M., Richmond, B. J., & Schousboe, J. T. (2006) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2006.05.006 · Cited by 151
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club
Devogelaer, J., Goemaere, S., Boonen, S., Body, J., Kaufman, J., Reginster, J., Rozenberg, S., & Boutsen, Y. (2005) · Osteoporosis International · doi:10.1007/s00198-005-2032-z · Cited by 144
Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial
Saag, K. G., Pannacciulli, N., Geusens, P., Adachi, J. D., Messina, O. D., Morales‐Torres, J., Emkey, R. D., Butler, P. W., Yin, X., & Lems, W. F. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40874 · Cited by 139
Glucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularity
Weinstein, R. S. (2009) · Bone · doi:10.1016/j.bone.2009.06.030 · Cited by 136
Prevalence and predictors of fragility fractures in systemic lupus erythematosus
Yee, C., Crabtree, N. J., Skan, J., Amft, N., Bowman, S., Situnayake, D., & Gordon, C. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018127 · Cited by 130
2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis
Briot, K., Cortet, B., Roux, C., Fardet, L., Abitbol, V., Bacchetta, J., Buchon, D., Debiais, F., Guggenbuhl, P., Laroche, M., et al. (2014) · Joint Bone Spine · doi:10.1016/j.jbspin.2014.10.001 · Cited by 130
Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization
Yao, W., Cheng, Z., Pham, A., Busse, C., Zimmermann, E. A., Ritchie, R. O., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23954 · Cited by 128
Spine fracture prevalence in a nationally representative sample of US women and men aged ≥40 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013-2014
Cosman, F., Krege, J. H., Looker, A. C., Schousboe, J. T., Fan, B., Sarafrazi, N., Shepherd, J., Krohn, K., Steiger, P., Wilson, K. E., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3948-9 · Cited by 128
High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA, reflects vertebral fracture status in men with glucocorticoid-induced osteoporosis
Graeff, C., Marín, F., Petto, H., Kayser, O., Reisinger, A., Peña, J. A., Zysset, P. K., & Glüer, C. (2012) · Bone · doi:10.1016/j.bone.2012.10.036 · Cited by 128
Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series
Armamento‐Villareal, R., Napoli, N., Diemer, K., Watkins, M. P., Civitelli, R., Teitelbaum, S. L., & Novack, D. V. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9263-5 · Cited by 122
Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength
Yao, W., Dai, W., Jiang, L., Lay, E. Y.-A., Zhong, Z. A., Ritchie, R. O., Li, X., Ke, H. Z., & Lane, N. E. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3308-6 · Cited by 116
Glucocorticoid-induced Osteoporosis
Whittier, X., & Saag, K. G. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.005 · Cited by 116
Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines
Mazziotti, G., Formenti, A. M., Adler, R. A., Bilezikian, J. P., Grossman, A. B., Sbardella, E., Minisola, S., & Giustina, A. (2016) · Endocrine · doi:10.1007/s12020-016-1146-8 · Cited by 115
Progression of Vertebral Fractures Despite Long-Term Biochemical Control of Acromegaly: A Prospective Follow-up Study
Claessen, K. M. J. A., Kroon, H. M., Pereira, A. M., Appelman-Dijkstra, N. M., Verstegen, M. J., Kloppenburg, M., Hamdy, N. A. T., & Biermasz, N. R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2695 · Cited by 111
Understanding Bone Strength Is Not Enough
Hernandez, C. J., & van der Meulen, M. C. H. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3078 · Cited by 110
Skeletal Aging
Sfeir, J. G., Drake, M. T., Khosla, S., & Farr, J. N. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.03.011 · Cited by 112
Important Determinants of Bone Strength
Friedman, A. (2006) · JCR Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000208612.33819.8c · Cited by 111
Autoimmune Myopathies: Updates on Evaluation and Treatment
McGrath, E. R., Doughty, C. T., & Amato, A. A. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-00676-2 · Cited by 103
Osteoporosis
Khandelwal, S., & Lane, N. E. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.10.009 · Cited by 103
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Rossi, C. M., & Comite, G. D. (2008) · New England Journal of Medicine · doi:10.1056/nejmc073408 · Cited by 102
Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis
Balasubramanian, A., Wade, S. W., Adler, R. A., Lin, C. J. F., Maricic, M. J., O’Malley, C. D., Saag, K. G., & Curtis, J. R. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3646-z · Cited by 103
Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial
STOCH, S. A., SAAG, K. G., GREENWALD, M., SEBBA, A. I., COHEN, S., VERBRUGGEN, N., GIEZEK, H., WEST, J., & SCHNITZER, T. J. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081207 · Cited by 100
Self-citation
Glucocorticoids: Complications to Anticipate and Prevent
Gensler, L. S. (2013) · The Neurohospitalist · doi:10.1177/1941874412458678 · Cited by 100
Osteoporosis Associated with Excess Glucocorticoids
Shaker, J. L., & Lukert, B. P. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.014 · Cited by 100
Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture
Leib, E. S., Saag, K. G., Adachi, J. D., Geusens, P., Binkley, N., McCloskey, E. V., & Hans, D. B. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.05.014 · Cited by 99
Osteoporosis Associated with Chronic Obstructive Pulmonary Disease
Okazaki, R., Watanabe, R., & Inoue, D. (2016) · Journal of Bone Metabolism · doi:10.11005/jbm.2016.23.3.111 · Cited by 96
Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes
Gado, M., Baschant, U., Hofbauer, L. C., & Henneicke, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.835720 · Cited by 95
Minireview: Live and Let Die: Molecular Effects of Glucocorticoids on Bone Cells
Hofbauer, L. C., & Rauner, M. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0069 · Cited by 91
Glucocorticoids, Inflammation and Bone
Güler-Yüksel, M., Hoes, J. N., Bultink, I. E. M., & Lems, W. F. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0335-7 · Cited by 92
Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency
Chakhtoura, Z., Bachelot, A., Samara-Boustani, D., Ruiz, J.-C., Donadille, B., Dulon, J., Christin-Maître, S., Bouvattier, C., Raux-Demay, M.-C., Bouchard, P., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0887 · Cited by 90
Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy–Induced Osteoporosis Treated With Alendronate or Teriparatide
Saag, K. G., Agnusdei, D., Hans, D. B., Kohlmeier, L., Krohn, K., Leib, E. S., Maclaughlin, E. J., Alam, J., Simonelli, C., Taylor, K. A., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39726 · Cited by 90
Glucocorticoid suppression of osteocyte perilacunar remodeling is associated with subchondral bone degeneration in osteonecrosis
Fowler, T. W., Acevedo, C., Mazur, C. M., Hall‐Glenn, F., Fields, A. J., Bale, H., Ritchie, R. O., Lotz, J. C., Vail, T. P., & Alliston, T. N. (2017) · Scientific Reports · doi:10.1038/srep44618 · Cited by 90
The Pathophysiological Sequence of Glucocorticoid-Induced Osteonecrosis of the Femoral Head in Male Mice
Weinstein, R. S., Hogan, E. A., Borrelli, M. J., Liachenko, S. M., O’Brien, C. A., & Manolagas, S. C. (2017) · Endocrinology · doi:10.1210/en.2017-00662 · Cited by 88
Clinical reviews in allergy and immunology
Leung, D. Y. M., Ledford, D. K., Wechsler, M. E., Fulkerson, P. C., Bochner, B. S., Gauvreau, G. M., Gleich, G. J., Henkel, T., Kolbeck, R., Mathur, S. K., et al. (2012) · Cited by 87
Assessment of vertebral microarchitecture in overt and mild Cushing's syndrome using trabecular bone score
Vinolas, H., Grouthier, V., Mehsen-Cêtre, N., Boisson, A., Winzenrieth, R., Schaeverbeke, T., Mesguich, C., Bordenave, L., & Tabarin, A. (2018) · Clinical Endocrinology · doi:10.1111/cen.13743 · Cited by 87
Diabetes and bone
Hygum, K., Starup‐Linde, J., & Langdahl, B. L. (2019) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2019.05.001 · Cited by 87
From bone biology to clinical outcome: state of the art and future perspectives
Schett, G. A., Saag, K. G., & Bijlsma, J. W. J. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.135061 · Cited by 86
Integrins, growth factors, and the osteoclast cytoskeleton
Zou, W., & Teitelbaum, S. L. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05245.x · Cited by 84
A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children
Hansen, K. E., Kleker, B., Safdar, N., & Bartels, C. M. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.02.002 · Cited by 87
Glucocorticoids and osteocyte autophagy
Yao, W., Dai, W., Jiang, J. X., & Lane, N. E. (2013) · Bone · doi:10.1016/j.bone.2013.01.034 · Cited by 82
Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system
Tanaka, Y., & Ohira, T. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.03.006 · Cited by 81
Osteoporosis in Chronic Obstructive Pulmonary Disease
Sarkar, M. S., Bhardwaj, R., Madabhavi, I., & Khatana, J. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s22803 · Cited by 84
Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
Pereira, R. M. R., de Carvalho, J. F., de Paula, A. P., Zerbini, C. A. F., Domiciano, D. S., Gonçalves, H., Danowski, J. S., Neto, J. F. M., de Mendonça, L. M. C., Bezerra, M. C., et al. (2012) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042012000400009 · Cited by 80
Frailty is independently associated with mortality in 11 001 patients with inflammatory bowel diseases
Kochar, B. D., Cai, W., Cagan, A., & Ananthakrishnan, A. N. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15821 · Cited by 80
Biologic therapies and systemic bone loss in rheumatoid arthritis
Dimitroulas, T., Nikas, S. N., Trontzas, P., & Kitas, G. D. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.03.015 · Cited by 80
How to prevent steroid induced osteoporosis
Sambrook, P. N. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018556 · Cited by 78
Management of Osteoporosis in Patients Living With HIV—A Systematic Review and Meta-analysis
Starup‐Linde, J., Rosendahl, S. B., Storgaard, M., & Langdahl, B. L. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002207 · Cited by 77
Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Candelas, G., et al. (2018) · Reumatología Clínica · doi:10.1016/j.reuma.2018.09.004 · Cited by 81

Authors: Van Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., & Cooper, C.
Affiliations: Procter & Gamble (United Kingdom) (GB)
University of Aberdeen (GB)
University of Southampton (GB)
ORCID: Laan, R. F.
Cohen, S.
Reid, D. M.
Cooper, C.
Venue: Arthritis & Rheumatism
Publisher: Wiley
Published: 2003-11
Volume: 48
Issue: 11
Pages: 3224-3229
ISSN: 0004-3591 (ISSN-L)
1529-0131
DOI: 10.1002/art.11283
OpenAlex: W1978136096
Cited by: 559
References: 29
Citations by year: 2026: 6 · 2025: 14 · 2024: 11 · 2023: 13 · 2022: 21 · 2021: 27 · 2020: 28 · 2019: 30 · 2018: 36 · 2017: 30 · 2016: 28 · 2015: 36 · 2014: 29 · 2013: 29 · 2012: 23
FWCI: 21.19
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 3 d)
Locations: Arthritis & Rheumatism (publishedVersion)
PubMed (publishedVersion)
Research Explorer (The University of Manchester) (publishedVersion)
ePrints Soton (University of Southampton) (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: vertebral fractures, oral corticosteroids, bone mineral density, fracture risk prediction, risedronate, postmenopausal women, glucocorticoid dose, osteoporosis, lumbar spine bone mineral density, T-score thresholds
MeSH terms: Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Femur Neck, Glucocorticoids, Humans, Lumbar Vertebrae, Male, Middle Aged, Prednisone, Risk, Risk Factors, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Postmenopause

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks